Nicox's ZERVIATE Reaches Chinese Market Through Ocumension Partnership

Nicox SA has announced the first commercial sale of ZERVIATE in China, facilitated by its partner Ocumension Therapeutics. This eye drop, containing the antihistamine cetirizine, addresses ocular itching linked to allergic conjunctivitis. Approved in China in September 2024, ZERVIATE fills a significant medical gap, particularly benefiting young children.

This sale marks a significant step in the partnership between Nicox and Ocumension, which commenced in 2018. Ocumension has an enhanced leadership position in China’s ophthalmology sector, owing to strategic acquisitions and efficient operations, including a swift manufacturing campaign. The collaboration also covers another key development, NCX 470, currently in Phase 3 trials in China.

The ZERVIATE agreement allows Nicox to earn up to $17.2 million in sales milestones and royalties between 5% and 9% on net sales, strengthening its revenue stream.